Nuwellis Inc (NUWE)
Official siteHEALTHCARE • MEDICAL DEVICES • NASDAQ
Market Cap: $2.65M
Last updated: Nov 17, 2026 at 4:18 PM ET
Nuwellis Inc (NUWE) Stock Chart
Nuwellis (NUWE) has a latest price of $4.10 on Nov 17, 2026, 99.7% below its 52-week high of $1,556.07. Its price fell 99.5% over the past 12 months. The month-end price fell 100.0% over the 10 years through Oct 2026, a compound annual decline of 93.1%.
Price Chart
From Oct 2016 to Oct 2026, its highest month-end close was $4,087,787,195,686.85 in Dec 2016 and its lowest $5.68 in Oct 2026, adjusted for splits.
Month-end closes, adjusted for splits. Dividends are not included.
Chart NUWE with Advanced Charting
Daily candlesticks, valuation multiples, side-by-side comparisons and drawings for NUWE.
Free with a GNG account. No credit card.
Price Performance
Over the past 3 months the price fell 61.1%, and over 6 months it fell 98.7%. The month-end price fell 100.0% over the 3 years through Oct 2026, a compound annual decline of 97.5%.
| Period | Change |
|---|---|
| 1 month | -18.4% |
| 3 months | -61.1% |
| 6 months | -98.7% |
| 12 months | -99.5% |
| 12 months, with dividends | -99.5% |
| Period | Change | Per year |
|---|---|---|
| 3 years | -100.0% | -97.5% |
| 5 years | -100.0% | -96.4% |
| 10 years | -100.0% | -93.1% |
Price by Year
Its best calendar year was 2020, when the price fell 73.0%, and its weakest was 2017, when it fell 98.4%.
| Year | Close | Change |
|---|---|---|
| 2026 through Oct 2026 | $5.68 | -99.0% |
| 2025 | $547.61 | -96.3% |
| 2024 | $14,677.97 | -94.5% |
| 2023 | $268,582.86 | -94.6% |
| 2022 | $4,956,461.11 | -90.6% |
| 2021 | $52,708,634.96 | -83.6% |
| 2020 | $322,262,443.58 | -73.0% |
| 2019 | $1,194,073,707.04 | -87.4% |
| 2018 | $9,493,628,815.36 | -85.9% |
| 2017 | $67,283,809,301.81 | -98.4% |
Trading Range
The price is 30.8% below its 50-day average of $5.92 and 97.8% below its 200-day average of $185.34.
| Measure | Value | Price vs |
|---|---|---|
| Latest price (Nov 17, 2026) | $4.10 | |
| 52-week high | $1,556.07 | -99.7% |
| 52-week low | $2.52 | +62.4% |
| 50-day average | $5.92 | -30.8% |
| 200-day average | $185.34 | -97.8% |
Price Risk
Over 3 years, its largest fall from a peak was 100.0%.
| Measure | Value |
|---|---|
| 1-year beta | 4.07 |
| Largest fall, 1 year | -99.8% |
| Largest fall, 3 years | -100.0% |
Advanced Charting Features
Advanced Charting is free with a GNG account, and signed-in members get it in place of the price chart above.
- Valuation multiples. Daily P/E, price to sales, cash flow and book value, PEG and PEGY, drawn behind the price wherever the company's data supports them.
- Price charts and drawings. Candlestick, OHLC, line and area charts with volume and earnings, dividend and split markers, plus trend lines, levels and notes kept in your account.
- Side-by-side compare. Two stocks next to each other on one metric and time span, each chart with its own price scale.
- Projections and saved views. Pick a start and an end point to see the price return, dividends and total return between them, and save views to open later.
Frequently Asked Questions About NUWE
What is NUWE's 1-year price change?
Nuwellis's price fell 99.5% over the past 12 months. With dividends included, the 12-month total return was -99.5%.
What is NUWE's 5-year price change?
Nuwellis's month-end price fell 100.0% over the 5 years through Oct 2026, a compound annual decline of 96.4%. These figures leave out dividends.
What is NUWE's 52-week high and low?
Nuwellis's 52-week high is $1,556.07 and its 52-week low is $2.52. Its latest price of $4.10 on Nov 17, 2026 is 99.7% below the high.
What is NUWE's beta?
Nuwellis's 1-year beta against the S&P 500 is 4.07, so its price has moved more than the market over the past year. Its largest fall from a peak over the past year was 99.8%.
Is the NUWE chart free?
Yes. Advanced Charting for NUWE is free with a GNG account, and no credit card is needed. It adds daily candlestick and line charts with volume, valuation multiples, side-by-side comparisons, drawings and saved views.
NUWE pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors, Government Contracts